Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Collegium Pharmaceutical (COLL) Non-Current Debt: 2016-2024

Historic Non-Current Debt for Collegium Pharmaceutical (COLL) over the last 8 years, with Dec 2024 value amounting to $550.7 million.

  • Collegium Pharmaceutical's Non-Current Debt fell 10.63% to $505.6 million in Q3 2025 from the same period last year, while for Sep 2025 it was $505.6 million, marking a year-over-year decrease of 10.63%. This contributed to the annual value of $550.7 million for FY2024, which is 148.40% up from last year.
  • Collegium Pharmaceutical's Non-Current Debt amounted to $550.7 million in FY2024, which was up 148.40% from $221.7 million recorded in FY2023.
  • In the past 5 years, Collegium Pharmaceutical's Non-Current Debt ranged from a high of $550.7 million in FY2024 and a low of $61.7 million during FY2021.
  • Its 3-year average for Non-Current Debt is $390.0 million, with a median of $397.6 million in 2022.
  • Its Non-Current Debt has fluctuated over the past 5 years, first skyrocketed by 1,334.97% in 2020, then slumped by 44.23% in 2023.
  • Over the past 5 years, Collegium Pharmaceutical's Non-Current Debt (Yearly) stood at $110.0 million in 2020, then crashed by 43.95% to $61.7 million in 2021, then skyrocketed by 544.73% to $397.6 million in 2022, then plummeted by 44.23% to $221.7 million in 2023, then surged by 148.40% to $550.7 million in 2024.